New hope for lymphoma patients: experimental drug combo enters testing
NCT ID NCT07398638
Summary
This study is testing whether adding a new drug called lisatoclax to standard lymphoma treatments is safe and effective for people with untreated diffuse large B-cell lymphoma. Researchers will enroll 122 patients to receive either lisatoclax plus R-CHOP or lisatoclax plus Pola-R-CHP. The main goals are to find the safest dose and see how many patients achieve complete remission of their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.